First Manhattan’s Ligand Pharmaceuticals LGND Stock Holding History

First Manhattan’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-160	Closed	-$11K	–	1623
2022 Q1	$11K	Hold	160	–	–	﹤0.01%	1261
2021 Q4	$15K	Hold	160	–	–	﹤0.01%	1214
2021 Q3	$13K	Hold	160	–	–	﹤0.01%	1230
2021 Q2	$13K	Hold	160	–	–	﹤0.01%	1230
2021 Q1	$15K	Buy	+160	New	+$15.1K	﹤0.01%	1173
2013 Q4	–	Sell	-2,348	Closed	-$63K	–	1395
2013 Q3	$63K	Hold	2,348	–	–	﹤0.01%	879
2013 Q2	$69K	Buy	+2,348	New	+$42.2K	﹤0.01%	866

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

First Manhattan's LGND Position: Q2 2022 in Review

First Manhattan sold out of Ligand Pharmaceuticals (LGND) in Q2 2022, closing a stake of 160 shares — an estimated $11K sold.

First Manhattan first reported a position in LGND in Q2 2013 and held it in 7 quarters. The position peaked at $69K in Q2 2013. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.

First Manhattan reported no remaining Ligand Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
First Manhattan sold 160 Ligand Pharmaceuticals shares in Q2 2022, an estimated $11K.
First Manhattan first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 7 quarters.
First Manhattan's Ligand Pharmaceuticals position peaked at $69K in Q2 2013.
197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.

Based on First Manhattan's 13F filing for Q2 2022, filed 15 Aug 2022.